Introduction Long-term safety and efficacy of upadacitinib in patients with active ankylosing spondylitis (AS) has not been previously reported.Methods In SELECT-AXIS 1, patients receiving placebo ...

Objectives We aimed to investigate the prevalence of dyslipidemia in patients with osteoarthritis (OA) and whether OA and dyslipidemia are associated.Methods We performed a systematic literature ...

Patients with psoriatic arthritis (PsA) have a higher prevalence of diabetes mellitus (DM) compared to the general population ...

Mader R, Verlaan JJ, Eshed I, et al. Diffuse idiopathic skeletal hyperostosis (DISH): where we are now and where to go next. RMD Open 2017;3:e000472.

van Straalen JW, Akay G, Kouwenberg CV, et al. Methotrexate therapy associated with a reduced rate of new-onset uveitis in patients with biological-naïve juvenile idiopathic arthritis. RMD Open 2023;9 ...

Kronzer VL, Davis JM, Hanson AC, et al. Association between sinusitis and incident rheumatic diseases: a population-based study. RMD Open 2024;10:e003622. In this article, the polymyalgia rheumatica ...

Objectives The window of opportunity (WOO) hypothesis suggests a limited time frame to stop rheumatoid arthritis (RA). We hypothesised that a WOO could either be represented by a hyperbolic (‘curved’) ...

Arevalo Salaet M, López-Medina C, Moreno M, et al. Association between HLA-B27 and peripheral spondyloarthritis phenotype: results from the ASAS perSpA study. RMD Open 2022;8:e002696. Doi: ...

To cite: Wang J, Bao C, Dai Q, et al. Efficacy and safety of jaktinib hydrochloride tablets in active axial spondyloarthritis: a multicentre, randomised, double-blind, placebo-controlled phase II ...

To cite: Buch MH, Aletaha D, Combe BG, et al. Efficacy and safety of filgotinib in patients with rheumatoid arthritis: week 156 interim results from a long-term extension study. RMD Open ...

To cite: Tanaka Y, Miyazaki Y, Kawanishi M, et al. Long-term safety and efficacy of anti-TNF multivalent VHH antibodies ozoralizumab in patients with rheumatoid arthritis. RMD Open 2024;10:e004480.

Background Janus kinase inhibitors are an effective option for achieving sustained remission or low disease activity in patients with rheumatoid arthritis (RA) following inadequate response to ...